Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma

Journal of Neuro-Oncology

Volumn 96, Issue 2, 2010, Pages 277-285

  Quon, H ^a   Hasbini, A ^b   Cougnard, J ^c   Djafari, L ^c   Lacroix, C ^d   Abdulkarim, B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Schering Plough ^*  (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

Angiogenesis; Oligodendroglioma; Survival

Indexed keywords

CD34 ANTIGEN; KI 67 ANTIGEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGE; ARTICLE; CANCER GRADING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FOLLOW UP; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; SEIZURE; SURVIVAL TIME; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; OLIGODENDROGLIOMA; PROGNOSIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 75049083101     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9961-x     Document Type: Article

References (42)

1. C Daumas-Duport P Varlet ML Tucker, et al. 1997 Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases J Neurooncol 34 37 59 10.1023/A:1005707203596 1:STN:280:DyaK2szltlyisw%3D%3D 9210052 (Pubitemid 27270251)
2. EG Shaw BW Scheithauer JR O'Fallon, et al. 1992 Oligodendrogliomas: the Mayo Clinic experience J Neurosurg 76 428 434 10.3171/jns.1992.76.3.0428 1:STN:280:DyaK387kvVGhsQ%3D%3D 1738022
3. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007
4. G Cairncross B Berkey E Shaw, et al. 2006 Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J Clin Oncol 24 2707 2714 10.1200/JCO.2005.04.3414 1:CAS:528: DC%2BD28XntV2hurg%3D 16782910 (Pubitemid 46630566)
5. MJ van den Bent AF Carpentier AA Brandes, et al. 2006 Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial J Clin Oncol 24 2715 2722 10.1200/JCO.2005.04.6078 16782911 (Pubitemid 46630567)
6. Quon H, Abdulkarim B (2008) Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev, Issue 2. Art. No.: CD007104. DOI: 10.1002/14651858.CD007104 (Pubitemid 351807223)
7. D Schiffer A Dutto P Cavalla, et al. 1999 Prognostic factors in oligodendroglioma Can J Neurol Sci 24 313 319
8. A Saito Y Nakazato 1999 Evaluation of malignant features in oligodendroglial tumors Clin Neuropathol 18 61 73 1:STN:280:DyaK1M3gs12iug%3D%3D 10192700
9. PC Burger CE Rawlings EB Cox RE McLendon SC Schold Jr DE Bullard 1987 Clinicopathologic correlations in the oligodendroglioma Cancer 59 1345 1352 10.1002/1097-0142(19870401)59:7<1345::AID-CNCR2820590719>3.0.CO;2-A 1:STN:280:DyaL2s7jtVKjsg%3D%3D 3545437 (Pubitemid 17035482)
10. P Celli I Nofrone L Palma, et al. 1994 Cerebral oligodendroglioma: prognostic factors and life history Neurosurgery 35 1018 1034 10.1097/00006123-199412000-00003 1:STN:280:DyaK2M7ptFOmtw%3D%3D 7885546
11. D Fortin GJ Cairncross RR Hammond 1999 Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment Neurosurgery 45 1279 1291 10.1097/00006123-199912000-00001 1:STN:280:DC%2BD3c%2FmsFOmsQ%3D%3D 10598694
12. C Giannini BW Scheithauer AL Weaver, et al. 2001 Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading J Neuropathol Exp Neurol 60 248 262 1:STN:280:DC%2BD3M7osVOitA%3D%3D 11245209
13. J Vaquero M Zurita C Morales, et al. 2001 Prognostic significance of the endothelial surface in low-grade resected oligodendrogliomas Br J Neurosurg 15 247 260 10.1080/02688690120057673 1:STN:280:DC%2BD3MvjtVGisA%3D%3D 11478061 (Pubitemid 32660961)
14. J Folkman 1990 What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 4 6 10.1093/jnci/82.1.4 1:STN:280: DyaK3c%2FnvF2qug%3D%3D 1688381
15. C Daumas-Duport ML Tucker H Kolles, et al. 1997 Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria J Neurooncol 34 61 78 10.1023/A:1005759220434 1:STN:280:DyaK2szltlyisA%3D%3D 9210053 (Pubitemid 27270252)
16. S Brem R Cotran J Folkman 1972 Tumor angiogenesis: a quantitative method for histologic grading J Natl Cancer Inst 48 347 356 1:STN:280: DyaE3s7itVCrsg%3D%3D 4347034
17. Kleihues P, Cavenee WK, eds (2000). Pathology and genetics: Tumors of the nervous system. In: WHO classification of tumors. Lyon (France): IARC press, 56-61
18. HH Engelhard A Stelea EJ Cochran 2002 Oligodendroglioma: pathology and molecular biology Surg Neurol 58 111 117 10.1016/S0090-3019(02)00751-6 12453646 (Pubitemid 35365906)
19. M LeBlanc J Crowley 1992 Relative risk trees for censored survival data Biometrics 48 411 425 10.2307/2532300 1:STN:280:DyaK38zksFGgtA%3D%3D 1637970
20. C Leighton B Fisher G Bauman, et al. 1997 Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation J Clin Oncol 15 1294 1301 1:STN:280:DyaK2szjs1GksQ%3D%3D 9193320
21. KH Plate G Breier HA Weich W Risau 1992 Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo Nature 359 845 848 10.1038/359845a0 1:CAS:528:DyaK38XmsV2gsb8%3D 1279432
22. CR Miller CP Dunham BW Scheithauer A Perry 2006 Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas J Clin Oncol 24 34 5419 5426 10.1200/JCO.2006.08.1497 17135643 (Pubitemid 46623175)
23. Kouwenhoven MC, Gorlia T, Kros J, et al. (2009). Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology. 2009 February 17
24. SH Bigner MR Matthews BK Rasheed, et al. 1999 Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization Am J Pathol 155 375 386 1:CAS:528:DyaK1MXls1Whs7s%3D 10433931
25. JS Smith A Perry TJ Borell, et al. 2000 Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas J Clin Oncol 18 636 645 1:STN:280:DC%2BD3c7itVyrsA%3D%3D 10653879
26. JM McDonald SJ See IW Tremont, et al. 2005 The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors Cancer 104 1468 1477 10.1002/cncr.21338 1:CAS:528:DC%2BD2MXhtFahsb%2FL 16088966 (Pubitemid 41356162)
27. S Bortolotto L Chiado-Piat P Cavalla, et al. 2000 CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas Int J Cancer 88 554 567 10.1002/1097-0215(20001115)88:4<554::AID-IJC6>3.0.CO;2-Q 1:CAS:528:DC%2BD3cXotVKitrk%3D 11058870 (Pubitemid 30805068)
28. A Perry KD Aldape DH George PC Burger 2004 Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendrogliomas Cancer 101 2318 2326 10.1002/cncr.20625 15470710 (Pubitemid 39458690)
29. AS Chan SY Leung MP Wong, et al. 1998 Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma Am J Surg Pathol 22 816 826 10.1097/00000478-199807000-00004 1:STN:280:DyaK1czjt1SjtQ%3D%3D 9669344 (Pubitemid 28328228)
30. SI Abdulrauf K Edvardsen KL Ho, et al. 1998 Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma J Neurosurg 88 513 520 10.3171/jns.1998.88. 3.0513 1:CAS:528:DyaK1cXhslGit7c%3D 9488306
31. T Pietsch MM Valter HK Wolf, et al. 1997 Expression and distribution of vascular endothelial growth factor protein in human brain tumors Acta Neuropathol 93 109 117 10.1007/s004010050591 1:CAS:528:DyaK2sXhvVertbk%3D 9039457 (Pubitemid 27060902)
32. C Christov H Adle-Biassette C Le Guerinel, et al. 1998 Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas Neuropathol Appl Neurobiol 24 29 35 10.1046/j.1365-2990.1998.00091.x 1:CAS:528:DyaK1cXitlCgs7o%3D 9549726 (Pubitemid 28105411)
33. C Godfraind E Rousseau MM Ruchoux, et al. 2003 Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas Neuropathol Appl Neurobiol 29 462 471 10.1046/j.1365-2990.2003.00484.x 1:CAS:528:DC%2BD3sXovFentbg%3D 14507338 (Pubitemid 37222720)
34. H Harada K Nakagawa S Iwata, et al. 1999 Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas Cancer Res 59 3783 3789 1:CAS:528: DyaK1MXltFCns7w%3D 10446996
35. J Jen JW Harper SH Bigner, et al. 1994 Deletion of p16 and p15 genes in brain tumors Cancer Res 54 6353 6358 1:CAS:528:DyaK2MXislamu7c%3D 7987828
36. P Varlet JS Guillamo F Nataf, et al. 2000 Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival Neuropathol Appl Neurobiol 26 379 389 10.1046/j.1365-2990.2000.00263.x 1:STN:280: DC%2BD3cvjvFCmsA%3D%3D 10931372 (Pubitemid 30609434)
37. DN Louis EC Holland JG Cairncross 2001 Glioma classification: a molecular reappraisal Am J Pathol 159 779 786 1:CAS:528:DC%2BD3MXnt12ms7o%3D 11549567
38. J Reifenberger G Reifenberger L Liu, et al. 1994 Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p Am J Pathol 145 1175 1190 1:CAS:528:DyaK2MXit1Wksb8%3D 7977648
39. PC Burger AY Minn JS Smith, et al. 2001 Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections Mod Pathol 14 842 853 10.1038/modpathol.3880400 1:STN:280: DC%2BD3MrhtVaisA%3D%3D 11557779 (Pubitemid 32889241)
40. JG Cairncross K Ueki MC Zlatescu, et al. 1999 Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90 1473 1479 10.1093/jnci/90.19.1473
41. B Thiessen JA Maguire K McNeil, et al. 2003 Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity J Neurooncol 64 271 278 10.1023/A:1025689004046 14558604 (Pubitemid 37203469)
42. N Hashimoto M Murakami Y Takahashi, et al. 2003 Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p Cancer 97 2254 2261 10.1002/cncr.11322 1:CAS:528: DC%2BD3sXjvVSjs7Y%3D 12712480 (Pubitemid 36444069)